Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.20 | 25.80 | 0.29% |
| CAC 40 | 8,111.86 | 5.70 | 0.07% |
| DAX 40 | 24,123.79 | 46.92 | 0.19% |
| Dow JONES (US) | 48,114.26 | 302.30 | -0.62% |
| FTSE 100 | 9,829.15 | 144.36 | 1.49% |
| HKSE | 25,468.78 | 233.37 | 0.92% |
| NASDAQ | 23,111.46 | 54.05 | 0.23% |
| Nikkei 225 | 49,512.28 | 128.99 | 0.26% |
| NZX 50 Index | 13,295.91 | 129.04 | -0.96% |
| S&P 500 | 6,800.26 | 16.25 | -0.24% |
| S&P/ASX 200 | 8,585.20 | 21.60 | 0.25% |
| SSE Composite Index | 3,870.28 | 45.47 | 1.19% |